OPC Pharmaceutical JSC (HOSE:OPC)
23,800
+1,250 (5.54%)
At close: Apr 10, 2026
OPC Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,122,987 | 968,576 | 1,004,887 | 1,171,614 | 1,123,728 | |
Revenue Growth (YoY) | 15.94% | -3.61% | -14.23% | 4.26% | 16.38% |
Cost of Revenue | 591,453 | 522,458 | 526,456 | 637,906 | 643,499 |
Gross Profit | 531,534 | 446,118 | 478,431 | 533,708 | 480,229 |
Selling, General & Admin | 399,245 | 311,684 | 332,311 | 355,073 | 313,516 |
Operating Expenses | 399,245 | 311,684 | 332,311 | 355,073 | 313,516 |
Operating Income | 132,289 | 134,434 | 146,120 | 178,636 | 166,713 |
Interest Expense | - | - | -334.55 | -925.2 | -4,819 |
Interest & Investment Income | 11,916 | 8,335 | 15,854 | 7,813 | 3,707 |
Earnings From Equity Investments | 1,932 | 1,535 | 838.45 | 797.74 | 172.88 |
Currency Exchange Gain (Loss) | 861.55 | 448.73 | 555.41 | 279.37 | 360.84 |
Other Non Operating Income (Expenses) | -6,114 | -7,627 | -7,710 | -6,677 | -6,894 |
EBT Excluding Unusual Items | 140,885 | 137,126 | 155,323 | 179,924 | 159,241 |
Gain (Loss) on Sale of Investments | 7,159 | - | - | - | - |
Pretax Income | 148,043 | 137,126 | 155,323 | 179,924 | 159,241 |
Income Tax Expense | 31,623 | 27,672 | 33,004 | 37,530 | 35,878 |
Earnings From Continuing Operations | 116,420 | 109,454 | 122,319 | 142,394 | 123,363 |
Minority Interest in Earnings | -539.6 | -2,394 | -84.74 | -266.22 | 3,014 |
Net Income | 115,881 | 107,060 | 122,234 | 142,128 | 126,377 |
Preferred Dividends & Other Adjustments | 17,382 | 12,652 | 18,677 | 14,010 | 13,416 |
Net Income to Common | 98,499 | 94,408 | 103,557 | 128,118 | 112,961 |
Net Income Growth | 8.24% | -12.41% | -14.00% | 12.46% | 19.46% |
Shares Outstanding (Basic) | 64 | 64 | 64 | 64 | 64 |
Shares Outstanding (Diluted) | 64 | 64 | 64 | 64 | 64 |
Shares Change (YoY) | - | - | - | - | -0.00% |
EPS (Basic) | 1537.82 | 1473.95 | 1616.80 | 2000.25 | 1763.61 |
EPS (Diluted) | 1537.82 | 1473.95 | 1616.80 | 2000.00 | 1763.61 |
EPS Growth | 4.33% | -8.83% | -19.16% | 13.40% | 19.16% |
Free Cash Flow | 41,675 | 12,147 | 243,317 | 28,688 | 181,809 |
Free Cash Flow Per Share | 650.66 | 189.65 | 3798.80 | 447.90 | 2838.51 |
Dividend Per Share | - | - | 1500.000 | 1500.000 | - |
Gross Margin | 47.33% | 46.06% | 47.61% | 45.55% | 42.73% |
Operating Margin | 11.78% | 13.88% | 14.54% | 15.25% | 14.84% |
Profit Margin | 8.77% | 9.75% | 10.30% | 10.94% | 10.05% |
Free Cash Flow Margin | 3.71% | 1.25% | 24.21% | 2.45% | 16.18% |
EBITDA | 153,844 | 156,735 | 169,015 | 201,454 | 189,215 |
EBITDA Margin | 13.70% | 16.18% | 16.82% | 17.20% | 16.84% |
D&A For EBITDA | 21,555 | 22,301 | 22,895 | 22,819 | 22,502 |
EBIT | 132,289 | 134,434 | 146,120 | 178,636 | 166,713 |
EBIT Margin | 11.78% | 13.88% | 14.54% | 15.25% | 14.84% |
Effective Tax Rate | 21.36% | 20.18% | 21.25% | 20.86% | 22.53% |
Revenue as Reported | 1,122,987 | 968,576 | 1,004,887 | 1,171,614 | 1,123,728 |
Advertising Expenses | 66,590 | 43,302 | 51,343 | 48,858 | 40,148 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.